FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma By Ogkologos - August 14, 2025 543 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR News on the Passing of the Lymphedema Treatment Act! January 23, 2023 The stories behind Teenage and Young Adult Cancer Awareness Month April 6, 2023 Political Interests Are A Major Adversary in the War on Women July 6, 2021 Weak Immunogenicity in Patients with Cancer After First Dose of mRNA-based... May 18, 2021 Load more HOT NEWS ‘Normal’ cells and ‘cancer’s surprising circular DNA’: Inside Cancer Grand Challenges... Tailored Psychotherapy Eases Depression in People with Advanced Cancer The power of partnership – the unique alliance taking on brain... Median Survival Times for Two Forms of Advanced Breast Cancer Have...
